Tables 2 from Tumor microenvironment modifications induced by afatinib in squamous cell carcinoma of the head and neck - a window-of-opportunity study (EORTC90111-24111)
Simon P. Beyaert(UCLouvain), Sandra Schmitz(Cliniques Universitaires Saint-Luc), Antonella Mendola(de Duve Institute), Yassine Lalami(Université Libre de Bruxelles), Axelle Loriot(de Duve Institute), Anne-Sophie Govaerts(European Organisation for Research and Treatment of Cancer), Lisa Licitra(University of Milan), Catherine Fortpied(European Organisation for Research and Treatment of Cancer), Jean‐Pascal Machiels(Cliniques Universitaires Saint-Luc), Nicolas D. Huyghe(European Society for Therapeutic Radiology and Oncology), Paul M. Clément(Universitair Ziekenhuis Leuven), Rose‐Marie Goebbels(UCLouvain), Paméla Baldin(Cliniques Universitaires Saint-Luc)
Cited by 0
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573